<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02511678</url>
  </required_header>
  <id_info>
    <org_study_id>CGC15-BNE098</org_study_id>
    <nct_id>NCT02511678</nct_id>
  </id_info>
  <brief_title>Multicenter Study of Cryoablation for Palliation of Painful Bone Metastases</brief_title>
  <acronym>MOTION</acronym>
  <official_title>Multicenter Study of Cryoablation for Palliation of Painful Bone Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galil Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galil Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy of cryoablation for palliation of painful metastases in
      patients with metastatic lesions involving bone who have failed, are not candidates for, or
      are not experiencing adequate pain relief from current pain therapies (e.g. radiation,
      analgesics).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with painful metastatic lesions involving bone who meet the eligibility criteria and
      who have been determined to be an appropriate candidate for cryoablation therapy will be
      offered enrollment into the study. Patients agreeing to participate will read and sign an
      informed consent form and thus become subjects in the study. Treatment will be performed
      using a Galil Medical cryoablation system and Galil Medical cryoablation needles. Subjects
      will have one cryoablation procedure and will be followed for up to 6 months for palliation
      of pain, quality of life and analgesic usage. Baseline and follow-up data will be collected
      for each subject via a web-based electronic data collection tool.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 15, 2016</start_date>
  <completion_date type="Anticipated">February 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in worst pain scores</measure>
    <time_frame>8 weeks post-cryoablation</time_frame>
    <description>The primary endpoint for this study will be measured as follows: improvement in self-reported pain scores defined by ≥ 2 point reduction in worst pain in the last 24 hours using the Brief Pain Inventory (BPI) from baseline to 8 weeks. A mean difference of 2 points reduction is considered clinically significant.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Number of subjects who respond to the cryoablation therapy</measure>
    <time_frame>8 weeks post-cryoablation</time_frame>
    <description>A responder is defined as a subject having ≥ 2 point reduction in the worst pain score in the last 24 hours using the BPI and no more than 25% increase in medication use (morphine equivalent) from baseline to 8 weeks</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of Life (QoL)</measure>
    <time_frame>Up to 24 weeks post-cryoablation</time_frame>
    <description>Quality of Life (QoL) as measured by the overall BPI pain interference average score from baseline to 1, 4, 8, 12, 16, 20, and 24 weeks after cryoablation</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of patients with a change in physical function</measure>
    <time_frame>Up to 24 weeks post-cryoablation</time_frame>
    <description>Change in physical function as measured by Karnofsky Performance Status (KPS) from baseline to 1, 4, 8, 12, 16, 20, and 24 weeks after cryoablation</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of patients with additional therapies</measure>
    <time_frame>Up to 24 weeks post-cryoablation</time_frame>
    <description>Additional therapies for persistent/recurrent pain associated with the index tumor under study or new bone metastases through 24 weeks</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of patients with a change in analgesic medications</measure>
    <time_frame>Up to 24 weeks post-cryoablation</time_frame>
    <description>Change in analgesic medications [morphine equivalent daily dosing and nonsteroidal antiinflammatory drug (NSAID) use] from baseline to 1, 4, 8, 12, 16, 20, and 24 weeks after cryoablation</description>
  </other_outcome>
  <other_outcome>
    <measure>Difference in worst pain scores</measure>
    <time_frame>Up to 24 weeks post-cryoablation</time_frame>
    <description>Difference in worst pain scores from baseline to 1, 4, 12, 16, 20, and 24 weeks after cryoablation as measured on the numeric 0 to 10 BPI scale</description>
  </other_outcome>
  <other_outcome>
    <measure>Difference in average pain scores</measure>
    <time_frame>Up to 24 weeks post-cryoablation</time_frame>
    <description>Difference in average pain scores from baseline to 1, 4, 8, 12, 16, 20, and 24 weeks after cryoablation as measured on the BPI numeric rating scale</description>
  </other_outcome>
  <other_outcome>
    <measure>Self-assessed Overall Treatment Effect (OTE)</measure>
    <time_frame>Up to 24 weeks post-cryoablation</time_frame>
    <description>Self-assessed Overall Treatment Effect (OTE) at 1, 4, 8, 12, 16, 20, and 24 weeks after cryoablation</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>Up to 30 days post-cryoablation</time_frame>
    <description>The safety endpoint for this study is to assess the incidence and severity of procedure or device- related adverse events</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Pain</condition>
  <condition>Neoplasm Metastasis</condition>
  <arm_group>
    <arm_group_label>Cryoablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will have one cryoablation procedure on one painful metastatic lesion involving bone using a Galil Medical cryoablation system and needles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cryoablation</intervention_name>
    <description>Cryoablation is an FDA-cleared technology for selective ablation and treatment of different kinds of benign and malignant conditions. For cryoablation in the palliation of painful bone metastases, subject preparation, anesthesia, intra-operative monitoring, and postoperative management are identical to those of standard cryoablation routinely performed at all clinical centers participating in this study.</description>
    <arm_group_label>Cryoablation</arm_group_label>
    <other_name>Cryotherapy</other_name>
    <other_name>Cryosurgery</other_name>
    <other_name>Visual-ICE Cryoablation System</other_name>
    <other_name>IceSeed Cryoablation Needle</other_name>
    <other_name>IceSphere Cryoablation Needle</other_name>
    <other_name>IceRod PLUS Cryoablation Needle</other_name>
    <other_name>IceEDGE 2.4 Cryoablation Needle</other_name>
    <other_name>IceFORCE 2.1 Cryoablation Needle</other_name>
    <other_name>IcePearl 2.1 Cryoablation Needle</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or older

          -  Metastatic disease involving bone with metastatic disease previously confirmed by
             prior biopsy; or Metastatic disease involving bone previously confirmed on imaging
             (e.g. CT or MRI) with known (biopsied) primary disease (primary bone cancer is
             excluded)

          -  Current analgesic therapies have failed, the subject is not a candidate for, OR the
             subject is not experiencing adequate pain relief from current pain therapies (e.g.
             radiation, analgesics)

          -  The 'worst pain' in the last 24 hours must be reported to be 4 or above on a scale of
             0 (no pain) to 10 (pain as bad as subject can imagine)

          -  Pain must be from one painful metastatic lesion involving the bone that is amenable to
             cryoablation with CT (additional less painful metastatic sites may be present)

          -  Cryoablation should be performed within 14 days of screening visit

          -  If taking hormonal therapy, use should be stable (no changes within 4 weeks prior to
             the cryoablation procedure)

          -  Karnofsky Performance Scale (KPS) score ≥60

          -  Life expectancy ≥ 3 months

          -  No debilitating medical or psychiatric illness that would preclude giving informed
             consent or receiving optimal treatment and follow-up

          -  Known coagulopathy or bleeding disorders are controlled

        Exclusion Criteria:

          -  Primary cancer is leukemia, lymphoma, or myeloma

          -  Tumor involves a weight-bearing long bone of the lower extremity with the tumor
             causing &gt; 50% loss of cortical bone

          -  Has undergone prior surgery at the tumor site or the index tumor has undergone
             previous surgery or ablation treatment

          -  Prior radiation therapy of the index tumor &lt;3 weeks prior to the screening visit

          -  Index tumor causing clinical or radiographic evidence of spinal cord or cauda equina
             compression/effacement

          -  Anticipated treatment of the index tumor that would require iceball formation within
             0.5 cm of the spinal cord, brain, other critical nerve structure, large abdominal
             vessel (possibly achieved with additional maneuvers such as hydrodissection)

          -  Index tumor involves the skull

          -  Currently pregnant, nursing, or wishing to become pregnant during the study

          -  Serious medical illness, including any of the following: uncontrolled congestive heart
             failure, uncontrolled angina, myocardial infarction, cerebrovascular event within 6
             months prior to the screening visit

          -  Concurrent participation in other studies that could affect the primary endpoint
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jack Jennings, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University Saint Louis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA Ronald Reagan Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Crittenton Hospital</name>
      <address>
        <city>Rochester</city>
        <state>Michigan</state>
        <zip>48307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University in St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.cancer.org/treatment/understandingyourdiagnosis/bonemetastasis/index</url>
    <description>American Cancer Society information on bone metastases</description>
  </link>
  <reference>
    <citation>Goldfarb HA. Nd:YAG laser laparoscopic coagulation of symptomatic myomas. J Reprod Med. 1992 Jul;37(7):636-8.</citation>
    <PMID>1387912</PMID>
  </reference>
  <reference>
    <citation>Phillips DR, Milim SJ, Nathanson HG, Haselkorn JS. Experience with laparoscopic leiomyoma coagulation and concomitant operative hysteroscopy. J Am Assoc Gynecol Laparosc. 1997 Aug;4(4):425-33.</citation>
    <PMID>9224575</PMID>
  </reference>
  <reference>
    <citation>Goldfarb HA. Laparoscopic coagulation of myoma (myolysis). Obstet Gynecol Clin North Am. 1995 Dec;22(4):807-19. Review.</citation>
    <PMID>8786884</PMID>
  </reference>
  <reference>
    <citation>COOPER IS, LEE AS. Cryostatic congelation: a system for producing a limited, controlled region of cooling or freezing of biologic tissues. J Nerv Ment Dis. 1961 Sep;133:259-63.</citation>
    <PMID>13881139</PMID>
  </reference>
  <reference>
    <citation>Saliken JC, Donnelly BJ, Rewcastle JC. The evolution and state of modern technology for prostate cryosurgery. Urology. 2002 Aug;60(2 Suppl 1):26-33. Review.</citation>
    <PMID>12206845</PMID>
  </reference>
  <reference>
    <citation>Rewcastle JC, Sandison GA, Saliken JC, Donnelly BJ, McKinnon JG. Considerations during clinical operation of two commercially available cryomachines. J Surg Oncol. 1999 Jun;71(2):106-11.</citation>
    <PMID>10389867</PMID>
  </reference>
  <reference>
    <citation>Rewcastle JC, Hahn LJ, Saliken JC, McKinnon JG. Use of a moratorium to achieve consistent liquid nitrogen cryoprobe performance. J Surg Oncol. 1997 Oct;66(2):110-3.</citation>
    <PMID>9354166</PMID>
  </reference>
  <reference>
    <citation>Gage AA. Current progress in cryosurgery. Cryobiology. 1988 Oct;25(5):483-6.</citation>
    <PMID>3197439</PMID>
  </reference>
  <reference>
    <citation>Gage AA, Guest K, Montes M, Caruana JA, Whalen DA Jr. Effect of varying freezing and thawing rates in experimental cryosurgery. Cryobiology. 1985 Apr;22(2):175-82.</citation>
    <PMID>3979086</PMID>
  </reference>
  <reference>
    <citation>Gage AA. Progress in cryosurgery. Cryobiology. 1992 Apr;29(2):300-4.</citation>
    <PMID>1582235</PMID>
  </reference>
  <reference>
    <citation>Homasson JP, Thiery JP, Angebault M, Ovtracht L, Maiwand O. The operation and efficacy of cryosurgical, nitrous oxide-driven cryoprobe. I. Cryoprobe physical characteristics: their effects on cell cryodestruction. Cryobiology. 1994 Jun;31(3):290-304.</citation>
    <PMID>8050273</PMID>
  </reference>
  <reference>
    <citation>Hamilton A, Hu J. An electronic cryoprobe for cryosurgery using heat pipes and thermoelectric coolers: a preliminary report. J Med Eng Technol. 1993 May-Jun;17(3):104-9.</citation>
    <PMID>8263903</PMID>
  </reference>
  <reference>
    <citation>Rabin Y, Julian TB, Wolmark N. A compact cryosurgical apparatus for minimally invasive procedures. Biomed Instrum Technol. 1997 May-Jun;31(3):251-8.</citation>
    <PMID>9181244</PMID>
  </reference>
  <reference>
    <citation>Rabin Y, Coleman R, Mordohovich D, Ber R, Shitzer A. A new cryosurgical device for controlled freezing. Cryobiology. 1996 Feb;33(1):93-105.</citation>
    <PMID>8812089</PMID>
  </reference>
  <reference>
    <citation>Rand RW, Rand RP, Eggerding FA, Field M, Denbesten L, King W, Camici S. Cryolumpectomy for breast cancer: an experimental study. Cryobiology. 1985 Aug;22(4):307-18.</citation>
    <PMID>2992882</PMID>
  </reference>
  <reference>
    <citation>Miller RH, Mazur P. Survival of frozen-thawed human red cells as a function of cooling and warming velocities. Cryobiology. 1976 Aug;13(4):404-14.</citation>
    <PMID>971585</PMID>
  </reference>
  <reference>
    <citation>Gage AA, Baust JM, Baust JG. Experimental cryosurgery investigations in vivo. Cryobiology. 2009 Dec;59(3):229-43. doi: 10.1016/j.cryobiol.2009.10.001. Epub 2009 Oct 13. Review.</citation>
    <PMID>19833119</PMID>
  </reference>
  <reference>
    <citation>McTaggart RA, Dupuy DE. Thermal ablation of lung tumors. Tech Vasc Interv Radiol. 2007 Jun;10(2):102-13. Review.</citation>
    <PMID>18070688</PMID>
  </reference>
  <reference>
    <citation>Callstrom MR, Charboneau JW. Image-guided palliation of painful metastases using percutaneous ablation. Tech Vasc Interv Radiol. 2007 Jun;10(2):120-31. Review.</citation>
    <PMID>18070690</PMID>
  </reference>
  <reference>
    <citation>McQuay HJ, Collins SL, Carroll D, Moore RA. Radiotherapy for the palliation of painful bone metastases. Cochrane Database Syst Rev. 2000;(2):CD001793. Review. Update in: Cochrane Database Syst Rev. 2013;11:CD001793.</citation>
    <PMID>10796822</PMID>
  </reference>
  <reference>
    <citation>Callstrom MR, Atwell TD, Charboneau JW, Farrell MA, Goetz MP, Rubin J, Sloan JA, Novotny PJ, Welch TJ, Maus TP, Wong GY, Brown KJ. Painful metastases involving bone: percutaneous image-guided cryoablation--prospective trial interim analysis. Radiology. 2006 Nov;241(2):572-80.</citation>
    <PMID>17057075</PMID>
  </reference>
  <reference>
    <citation>Coleman RE. Management of bone metastases. Oncologist. 2000;5(6):463-70. Review.</citation>
    <PMID>11110597</PMID>
  </reference>
  <reference>
    <citation>Goetz MP, Callstrom MR, Charboneau JW, Farrell MA, Maus TP, Welch TJ, Wong GY, Sloan JA, Novotny PJ, Petersen IA, Beres RA, Regge D, Capanna R, Saker MB, Grönemeyer DH, Gevargez A, Ahrar K, Choti MA, de Baere TJ, Rubin J. Percutaneous image-guided radiofrequency ablation of painful metastases involving bone: a multicenter study. J Clin Oncol. 2004 Jan 15;22(2):300-6.</citation>
    <PMID>14722039</PMID>
  </reference>
  <reference>
    <citation>Callstrom MR, Charboneau JW, Goetz MP, Rubin J, Wong GY, Sloan JA, Novotny PJ, Lewis BD, Welch TJ, Farrell MA, Maus TP, Lee RA, Reading CC, Petersen IA, Pickett DD. Painful metastases involving bone: feasibility of percutaneous CT- and US-guided radio-frequency ablation. Radiology. 2002 Jul;224(1):87-97.</citation>
    <PMID>12091666</PMID>
  </reference>
  <reference>
    <citation>Belfiore G, Tedeschi E, Ronza FM, Belfiore MP, Della Volpe T, Zeppetella G, Rotondo A. Radiofrequency ablation of bone metastases induces long-lasting palliation in patients with untreatable cancer. Singapore Med J. 2008 Jul;49(7):565-70.</citation>
    <PMID>18695866</PMID>
  </reference>
  <reference>
    <citation>Hurwitz MD, Ghanouni P, Kanaev SV, Iozeffi D, Gianfelice D, Fennessy FM, Kuten A, Meyer JE, LeBlang SD, Roberts A, Choi J, Larner JM, Napoli A, Turkevich VG, Inbar Y, Tempany CM, Pfeffer RM. Magnetic resonance-guided focused ultrasound for patients with painful bone metastases: phase III trial results. J Natl Cancer Inst. 2014 Apr 23;106(5). pii: dju082. doi: 10.1093/jnci/dju082.</citation>
    <PMID>24760791</PMID>
  </reference>
  <reference>
    <citation>Simon CJ, Dupuy DE. Percutaneous minimally invasive therapies in the treatment of bone tumors: thermal ablation. Semin Musculoskelet Radiol. 2006 Jun;10(2):137-44. Epub 2006 Apr 5. Review.</citation>
    <PMID>16598666</PMID>
  </reference>
  <reference>
    <citation>Ullrick SR, Hebert JJ, Davis KW. Cryoablation in the musculoskeletal system. Curr Probl Diagn Radiol. 2008 Jan-Feb;37(1):39-48. Review.</citation>
    <PMID>18054665</PMID>
  </reference>
  <reference>
    <citation>Maiwand MO. The role of cryosurgery in palliation of tracheo-bronchial carcinoma. Eur J Cardiothorac Surg. 1999 Jun;15(6):764-8.</citation>
    <PMID>10431856</PMID>
  </reference>
  <reference>
    <citation>Maiwand MO, Homasson JP. Cryotherapy for tracheobronchial disorders. Clin Chest Med. 1995 Sep;16(3):427-43. Review. Erratum in: Clin Chest Med 1995 Dec;16(4):ix.</citation>
    <PMID>8521698</PMID>
  </reference>
  <reference>
    <citation>Sanderson DR, Neel HB 3rd, Fontana RS. Bronchoscopic cryotherapy. Ann Otol Rhinol Laryngol. 1981 Jul-Aug;90(4 Pt 1):354-8.</citation>
    <PMID>6791555</PMID>
  </reference>
  <reference>
    <citation>Cozzi PJ, Lynch WJ, Collins S, Vonthethoff L, Morris DL. Renal cryotherapy in a sheep model; a feasibility study. J Urol. 1997 Feb;157(2):710-2.</citation>
    <PMID>8996403</PMID>
  </reference>
  <reference>
    <citation>Gage AA, Fazekas G, Riley EE Jr. Freezing injury to large blood vessels in dogs. With comments on the effect of experimental freezing of bile ducts. Surgery. 1967 May;61(5):748-54.</citation>
    <PMID>6024400</PMID>
  </reference>
  <reference>
    <citation>Gage AM, Montes M, Gage AA. Freezing the canine thoracic aorta in situ. J Surg Res. 1979 Nov;27(5):331-40.</citation>
    <PMID>513700</PMID>
  </reference>
  <reference>
    <citation>Ladd AP, Rescorla FJ, Baust JG, Callahan M, Davis M, Grosfeld JL. Cryosurgical effects on growing vessels. Am Surg. 1999 Jul;65(7):677-82.</citation>
    <PMID>10399979</PMID>
  </reference>
  <reference>
    <citation>Mandeville AF, McCabe BF. Some observations on the cryobiology of blood vessels. Laryngoscope. 1967 Aug;77(8):1328-50.</citation>
    <PMID>6034857</PMID>
  </reference>
  <reference>
    <citation>Callstrom MR, Dupuy DE, Solomon SB, Beres RA, Littrup PJ, Davis KW, Paz-Fumagalli R, Hoffman C, Atwell TD, Charboneau JW, Schmit GD, Goetz MP, Rubin J, Brown KJ, Novotny PJ, Sloan JA. Percutaneous image-guided cryoablation of painful metastases involving bone: multicenter trial. Cancer. 2013 Mar 1;119(5):1033-41. doi: 10.1002/cncr.27793. Epub 2012 Oct 12.</citation>
    <PMID>23065947</PMID>
  </reference>
  <reference>
    <citation>Cleeland CS. The measurement of pain from metastatic bone disease: capturing the patient's experience. Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6236s-6242s. Review.</citation>
    <PMID>17062707</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 27, 2015</study_first_submitted>
  <study_first_submitted_qc>July 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2015</study_first_posted>
  <last_update_submitted>October 6, 2017</last_update_submitted>
  <last_update_submitted_qc>October 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

